Seventy-five CHB patients completed the therapeutic schedule of immunization with
100 microgram of both HBsAg and HBcAg (HBsAg/HBcAg) (Center for Genetic Engineering and Biotechnology, Havana, Cuba), once in every two weeks (5 vaccinations through only
nasal route and followed by 5 additional vaccinations
via both nasal and subcutaneous route).
Seventy-six patients with CHB completed the treatment with Peg IFN (180 microgram, once weekly, subcutaneously for 48 consecutive weeks).